113 related articles for article (PubMed ID: 21763126)
1. Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C; Koscielny S; Ribrag V; Dromain C; Marzouk I; Bidault F; Bahleda R; Ferté C; Massard C; Soria JC
Eur J Cancer; 2011 Nov; 47(17):2512-6. PubMed ID: 21763126
[TBL] [Abstract][Full Text] [Related]
2. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
3. RECIST revisited: a review of validation studies on tumour assessment.
Therasse P; Eisenhauer EA; Verweij J
Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
[TBL] [Abstract][Full Text] [Related]
4. Individual patient data analysis to assess modifications to the RECIST criteria.
Bogaerts J; Ford R; Sargent D; Schwartz LH; Rubinstein L; Lacombe D; Eisenhauer E; Verweij J; Therasse P;
Eur J Cancer; 2009 Jan; 45(2):248-60. PubMed ID: 19095437
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of tumour response to treatment with targeted therapies: standard or targeted criteria?].
Menu Y
Bull Cancer; 2007; 94(7 Suppl):F231-9. PubMed ID: 17965002
[TBL] [Abstract][Full Text] [Related]
8. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
9. We should desist using RECIST, at least in GIST.
Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
[TBL] [Abstract][Full Text] [Related]
10. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
Trillet-Lenoir V; Freyer G; Kaemmerlen P; Fond A; Pellet O; Lombard-Bohas C; Gaudin JL; Lledo G; Mackiewicz R; Gouttebel MC; Moindrot H; Boyer JD; Chassignol L; Stremsdoerfer N; Desseigne F; Moreau JM; Hedelius F; Moraillon A; Chapuis F; Bleuse JP; Barbier Y; Heilmann MO; Valette PJ
Br J Radiol; 2002 Nov; 75(899):903-8. PubMed ID: 12466256
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
13. [Measurement of tumour response to cancer treatment: morphologic imaging role].
Ollivier L; Leclère J; Thiesse P; Di Stefano D; Vincent C
Bull Cancer; 2007 Feb; 94(2):171-7. PubMed ID: 17337386
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
[TBL] [Abstract][Full Text] [Related]
15. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
16. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
17. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
18. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.
Ferté C; Fernandez M; Hollebecque A; Koscielny S; Levy A; Massard C; Balheda R; Bot B; Gomez-Roca C; Dromain C; Ammari S; Soria JC
Clin Cancer Res; 2014 Jan; 20(1):246-52. PubMed ID: 24240109
[TBL] [Abstract][Full Text] [Related]
20. Observer variability in RECIST-based tumour burden measurements: a meta-analysis.
Yoon SH; Kim KW; Goo JM; Kim DW; Hahn S
Eur J Cancer; 2016 Jan; 53():5-15. PubMed ID: 26687017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
